Mirus Bio

Executive Summary

Mirus Bio, founded in 1995 and headquartered in Madison, Wisconsin, is a pioneering biotechnology company specializing in transfection reagents and systems for nucleic acid delivery. The company is a critical enabler of viral vector manufacturing, particularly adeno-associated virus (AAV) production, which is essential for gene and cell therapies. Mirus Bio's products are widely used in research and therapeutic production, addressing the growing demand for efficient and scalable manufacturing solutions in the gene therapy space. With over 25 years of experience, the company has established a strong reputation for innovation and reliability, positioning it as a key partner for biopharmaceutical companies developing advanced therapies. The gene and cell therapy market is expanding rapidly, driven by regulatory approvals and increasing R&D investment. As a leading supplier of transfection reagents, Mirus Bio is well-positioned to benefit from this trend. The company's focus on improving AAV production efficiency addresses a critical bottleneck in the industry, offering potential for significant revenue growth. While private and without disclosed funding, Mirus Bio's technological expertise and established customer base provide a solid foundation. However, competition from other reagent suppliers and alternative viral vector production methods could impact market share. Overall, Mirus Bio represents a stable, enabling technology play in the gene therapy ecosystem.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation transfection reagent for high-yield AAV production70% success
• Q4 2026Strategic partnership with a top gene therapy developer to supply reagents for clinical manufacturing60% success
• Q1 2027Series A or B financing round to expand manufacturing capacity and R&D50% success